Core Viewpoint - Cardina Health (CAH.US) reported revenue growth in its recent earnings report, leading to an increase in stock price and several institutions raising their target prices [1] Group 1: Earnings Performance - For the second quarter of fiscal year 2026, the company reported revenue of $65.627 billion, a year-over-year increase of 18.75% [2] - Net profit reached $467 million, reflecting a 16.75% year-over-year growth, primarily driven by the pharmaceutical distribution business [2] - Following the earnings release, the stock price experienced a fluctuation of 6.91% over the week, peaking at $230.81 on February 6 and dipping to $212.03 on February 5 [2] Group 2: Institutional Opinions - TD Cowen maintained a "Buy" rating on February 11, 2026, raising the target price from $233 to $251 based on better-than-expected earnings and industry outlook [3] - Among 20 institutions that provided insights in February, 80% rated the stock as "Buy" or "Hold," with an average target price of $251.13 [3] - The overall healthcare sales sector saw a rise of 1.05% during the same period [3] Group 3: Market Activity - On the earnings release date (February 5), trading volume reached 3.58 million shares, but decreased to 126,800 shares by February 11, indicating a drop in trading activity [4] - Prior to the earnings report, from November to December 2025, the company experienced several days of significant trading volume increases, such as a 12.24% surge on November 24 [4]

Core Viewpoint - Cardina Health reported Q2 FY2026 revenue of $65.627 billion and net profit of $4.67 billion, both showing year-on-year growth and exceeding market expectations [1][2]. Financial Report Analysis - For Q2 FY2026, Cardina Health achieved revenue of $65.627 billion, representing an 18.75% year-on-year increase; net profit reached $4.67 billion, up 16.75% year-on-year. The growth was primarily driven by the pharmaceutical distribution business, although the gross margin was 3.52% and net margin was 0.71%, reflecting the low-margin nature of the industry. The revenue surpassed market expectations of $64.9381 billion, with earnings per share at $2.63, exceeding the forecast of $2.37 [2]. Institutional Perspectives - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on the better-than-expected performance and industry outlook. Among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13. The internal database indicates a forecast of $2.63 for Q2 earnings per share, reflecting a year-on-year increase of 36.27% [3]. Recent Events - The Q2 performance was disclosed on February 5, 2026. TD Cowen raised the target price on February 11, coinciding with a 1.05% overall increase in the healthcare sales sector [4]. Recent Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 4.94%, with a high of $230.81 on February 6 and a low of $219.58 on February 10. The closing price on February 11 was $224.25, reflecting a single-day increase of 1.81% with a trading volume of 1.3133 million shares. On February 6, trading volume peaked at 2.2507 million shares, indicating active trading that later declined. The internal database shows a price change of -1.29% during this period, primarily influenced by post-earnings volatility [5].

Core Insights - Cardina Health reported Q2 revenue of $65.627 billion for fiscal year 2026, representing an 18.75% year-over-year increase; net profit reached $4.67 billion, up 16.75% year-over-year, driven primarily by the pharmaceutical distribution business, although gross margin was 3.52% and net margin was 0.71%, reflecting industry characteristics [1] Institutional Views - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on better-than-expected performance and industry outlook; among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13 [2] Recent Events - The financial report was disclosed before the market opened on February 5, 2026; TD Cowen raised the target price on February 11, coinciding with a 1.05% increase in the overall healthcare sales sector [3] Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 6.91%, with a high of $230.81 on February 6 and a low of $212.03 on February 5; the closing price on February 11 was $221.14, with a single-day increase of 0.39% and a volatility of 1.15%; trading volume peaked at 3.58 million shares on February 5, dropping to 126,790 shares by February 11, indicating a rise and subsequent decline in trading activity [4]